Liver News and Research

RSS

New technique developed to transform regular body cells into artificial stem cells

Scientists have overcome a key barrier to the clinical use of stem cells with a technique which transforms regular body cells into artificial stem cells without the need for introducing foreign genetic materials, which could be potentially harmful. The research, published in STEM CELLS, suggests that cells taken from a patient's eye can be "reprogrammed" to replace or restore cells lost to degenerative diseases.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has signed a long-term multi-project research and license collaboration agreement with Roche.

23 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

Canadian Cardiovascular Society to honor University of Alberta medical researcher

A University of Alberta medical researcher being hailed as a world leader in his field will receive a major national award for his pioneering work in the development of a new class of drugs for the treatment of heart failure.

23 Oct 2009

SAEC to collaborate with HMORN to improve the safe use of drugs

The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with the HMO Research Network (HMORN) to improve the safe use of drugs by exploring why the genetic makeup of some individuals makes them more likely to experience serious drug-related adverse events (SAEs).

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Study paves way for the creation of a stem cell library

The study, led by the University of Edinburgh's MRC Centre for Regenerative Medicine, paves the way for the creation of a stem cell library that can be used for in vitro hepatic disease models.

21 Oct 2009

Markers that cause primary liver cancer identified

Hepatocellular carcinoma (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year.

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled.

21 Oct 2009

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

UF scientists shed new light on old medical procedure

You might not know what it's called, but if you've had general anesthesia before surgery, especially after an accident, it is likely you have received Sellick's maneuver. That's when fingers are pressed against a patient's throat to prevent regurgitation and spilling of stomach contents into the airway and lungs while anesthesia is being administered.

21 Oct 2009

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

Clonality analyses may lead to further understanding of hepatocarcinogenesis

Focal nodular hyperplasia (FNH) is a lesion found in an otherwise normal liver, and is considered to be parenchyma overgrowth responsive to increased blood flow secondary to vascular malformations.

20 Oct 2009

Regulatory differences between mother and daughter cells shed new light on cell division

When mother and daughter cells are created each time a cell divides, they are not exactly alike. They have the same set of genes, but differ in the way they regulate them. New research now reveals that these regulatory differences between mother and daughter cells are directly linked to how they prepare for their next split.

20 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Liver News and Research

New technique developed to transform regular body cells into artificial stem cells

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Canadian Cardiovascular Society to honor University of Alberta medical researcher

SAEC to collaborate with HMORN to improve the safe use of drugs

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Study paves way for the creation of a stem cell library

Markers that cause primary liver cancer identified

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

UF scientists shed new light on old medical procedure

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Patients with chronic hepatitis C can benefit by drinking coffee

Clonality analyses may lead to further understanding of hepatocarcinogenesis

Regulatory differences between mother and daughter cells shed new light on cell division

UT student receives fellowship grant for pre-eclampsia research

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News